Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.

Macías J, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Pineda JA; COINS Study Team.

HIV Clin Trials. 2012 Mar-Apr;13(2):61-9. doi: 10.1310/hct1302-61.

PMID:
22510353
2.

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.

Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A, Merino D, de Los Santos-Gil I, Macías J, González-Serrano M, Camacho A, Parra-García G, Pineda JA; SEGURIDAD HEPÁTICA Study Team of the Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

J Antimicrob Chemother. 2011 Nov;66(11):2605-14. doi: 10.1093/jac/dkr357. Epub 2011 Sep 7.

3.

Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.

Merchante N, López-Cortés LF, Delgado-Fernández M, Ríos-Villegas MJ, Márquez-Solero M, Merino D, Pasquau J, García-Figueras C, Martínez-Pérez MA, Omar M, Rivero A, Macías J, Mata R, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Vıricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

AIDS Patient Care STDS. 2011 Jul;25(7):395-402. doi: 10.1089/apc.2011.0109. Epub 2011 Jun 20.

PMID:
21688986
4.

Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients.

Lapadula G, Costarelli S, Chatenoud L, Castelli F, Astuti N, Di Giambenedetto S, Quiros-Roldan E, Sighinolfi L, Ladisa N, Di Pietro M, Zoncada A, Di Filippo E, Gori A, Nasta P, Torti C; Italian MASTER Cohort.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):312-8. doi: 10.1097/QAI.0000000000000585.

PMID:
25723139
5.

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD.

Hepatology. 2002 Jan;35(1):182-9.

PMID:
11786975
6.

Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.

Pineda JA, Neukam K, Mallolas J, López-Cortés LF, Cartón JA, Domingo P, Moreno S, Iribarren JA, Clotet B, Crespo M, de Los Santos I, Ortega E, Knobel H, Jiménez-Expósito MJ, Macías J.

J Infect. 2012 Feb;64(2):204-11. doi: 10.1016/j.jinf.2011.10.016. Epub 2011 Nov 25.

PMID:
22138553
7.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;6:CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
8.

Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.

Palacios R, Vergara S, Rivero A, Aguilar I, Macías J, Camacho A, Lozano F, García-Lázaro M, Pineda JA, Torre-Cisneros J, Márquez M, Santos J.

HIV Clin Trials. 2006 Nov-Dec;7(6):319-23.

PMID:
17197379
9.

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD; 2NN Study Group.

Antivir Ther. 2005;10(4):489-98.

PMID:
16038474
10.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;5:CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
11.

Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.

Di Biagio A, Nicolini LA, Lorenzini P, Puoti M, Antinori A, Cozzi-Lepri A, Gori A, Vecchiet J, Mussini C, Andreoni M, Viscoli C, d'Arminio Monforte A, For The Icona Foundation Study Group.

HIV Clin Trials. 2014 Jul-Aug;15(4):151-60. doi: 10.1310/hct1504-151.

PMID:
25143024
12.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
13.

Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.

Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, Chokephaibulkit K.

Int J Infect Dis. 2008 Nov;12(6):e33-8. doi: 10.1016/j.ijid.2007.10.008. Epub 2008 Jun 24.

14.

Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.

Imaz A, Llibre JM, Navarro J, Curto J, Clotet B, Crespo M, Ferrer E, Saumoy M, Tiraboschi JM, Murillo O, Podzamczer D.

Antivir Ther. 2014;19(6):569-77. doi: 10.3851/IMP2736. Epub 2014 Jan 23.

PMID:
24458091
15.

Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.

Barreiro P, Rodríguez-Novoa S, Labarga P, Ruiz A, Jiménez-Nácher I, Martín-Carbonero L, Gonzalez-Lahoz J, Soriano V.

J Infect Dis. 2007 Apr 1;195(7):973-9. Epub 2007 Feb 20.

16.

Hepatotoxicity in patients prescribed efavirenz or nevirapine.

Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, Klinker H, Petzold D, Hartmann M.

Eur J Med Res. 2008 Jul 28;13(7):343-8.

PMID:
18700192
17.

Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.

Jarrin I, Hernández-Novoa B, Alejos B, Santos I, Lopez-Aldeguer J, Riera M, Gutiérrez F, Rubio R, Antela A, Blanco JR, Moreno S; Cohort of the Spanish HIV Research Network (CoRIS).

HIV Med. 2014 Oct;15(9):547-56. doi: 10.1111/hiv.12144. Epub 2014 Mar 24.

PMID:
24655804
18.

Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.

Gleason RL Jr, Caulk AW, Seifu D, Parker I, Vidakovic B, Getenet H, Assefa G, Amogne W.

PLoS One. 2015 Apr 27;10(4):e0117125. doi: 10.1371/journal.pone.0117125. eCollection 2015.

19.

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.

Keiser P, Nassar N, White C, Koen G, Moreno S.

HIV Clin Trials. 2002 Jul-Aug;3(4):296-303.

PMID:
12187503
20.

Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.

Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, Gwet H, Koulla-Shiro S, Ducos J, Mpoudi-Ngolé E, Molinari N, Delaporte E.

BMC Public Health. 2010 Mar 1;10:105. doi: 10.1186/1471-2458-10-105.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk